Crown raises $28.8M for oncology work

Santa Clara, CA-based Crown Biosciences has raised $28.8 million in a third round of venture financing, according to Xconomy. The cancer drug developer says it plans to use the funding to expand services in integrated cancer drug discovery and translational oncology, as well as to fund new initiatives in other therapeutic areas. OrbiMed Advisors Caduceus Asia Partners Fund, Argonaut Private Equity, the CID Group, IBT and CDIB Capital Investment led the round. Crown release | Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.